Invex Therapeutics is developing Presendin™, a reformulated GLP-1 receptor agonist, to treat neurological conditions characterized by elevated intracranial pressure. By reducing cerebrospinal fluid secretion, Presendin™ aims to offer a non-invasive pharmacological option for patients with conditions like Idiopathic Intracranial Hypertension (IIH).
Funding
$26M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Neurological conditions such as Idiopathic Intracranial Hypertension (IIH), acute stroke, and traumatic brain injury are often characterized by elevated intracranial pressure (ICP). Current treatment options for these conditions are limited, with few pharmacological interventions available, and often involve invasive surgical procedures.
Solution
Invex Therapeutics is repurposing Exenatide, a GLP-1 receptor agonist approved for type II diabetes, as Presendin™ for the treatment of neurological conditions involving elevated ICP. The company's development strategy focuses on reformulating Exenatide to effectively reduce cerebrospinal fluid (CSF) secretion, thereby lowering intracranial pressure. Presendin™ has received Orphan Drug Designation for IIH from both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), underscoring its potential to address a significant unmet medical need. The company is advancing Presendin™ through clinical trials, including a Phase III registration trial for IIH, with the objective of gaining regulatory approval across major jurisdictions.
Target Audience
The primary target audience includes patients diagnosed with neurological conditions associated with elevated intracranial pressure, particularly Idiopathic Intracranial Hypertension (IIH), as well as healthcare providers and regulatory bodies involved in neurology and neurosurgery.
Features
- Repurposing of Exenatide, an established GLP-1 receptor agonist, for neurological indications.
- Reformulation of Exenatide to target reduction of cerebrospinal fluid (CSF) secretion.
- Orphan Drug Designation for Idiopathic Intracranial Hypertension (IIH) from EMA and FDA.
- Extensive intellectual property portfolio related to the repurposed drug.
- Ongoing Phase III clinical trial (IIH EVOLVE) for Presendin™ in IIH.
- Exploration of potential applications in acute stroke and traumatic brain injury.
- Collaboration with Tessara Therapeutics utilizing their ADBrain™ 3D human brain model for Alzheimer's Disease research.